Evidence map›Paper›PMID 39713707›Full record

ArticleACS omega2024

Exploring the Mechanisms Underlying Cellular Uptake and Activation of Dendritic Cells by the GK-1 Peptide.

Jacquelynne Cervantes-Torres, Juan A Hernández-Aceves, Julián A Gajón Martínez, Diego Moctezuma-Rocha, Ricardo Vázquez Ramírez, Sergio Sifontes-Rodríguez, Gemma L Ramírez-Salinas, Luis Mendoza Sierra, Laura Bonifaz Alfonzo, Edda Sciutto and 1 more

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Toxicology reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jacquelynne Cervantes-TorresDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México MX 04510, Mexico.
Juan A Hernández-AcevesDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México MX 04510, Mexico.
Julián A Gajón MartínezUnidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México MX 06600, Mexico.
Diego Moctezuma-RochaDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México MX 04510, Mexico.
Ricardo Vázquez RamírezDepartamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Sede Tercer Circuito Exterior Edificio C 1er Piso, C-146, Ciudad de México MX 04510, Mexico.
Sergio Sifontes-RodríguezInvestigador por México del CONAHCyT adscrito al Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Sede Circuito Escolar Edificio A 1er Piso, Ciudad de México MX 04510, Mexico.
Gemma L Ramírez-SalinasDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México MX 04510, Mexico.
Luis Mendoza SierraDepartamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Sede Tercer Circuito Exterior Edificio C 1er Piso, C-146, Ciudad de México MX 04510, Mexico.
Laura Bonifaz AlfonzoUnidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades, CMN Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México MX 06600, Mexico.
Edda SciuttoDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México MX 04510, Mexico.
Gladis FragosoDepartamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México MX 04510, Mexico.ORCID https://orcid.org/0000-0003-3885-1858

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of peptides for cancer immunotherapy is a promising and emerging approach that is being intensively explored worldwide. One such peptide, GK-1, has been shown to delay the growth of triple-negative breast tumors in mice, reduce their metastatic capacity, and reverse the intratumor immunosuppression that characterizes this model. Herein, it is demonstrated that GK-1 is taken up by bone marrow dendritic cells in a dose-dependent manner 15 min after exposure, more efficiently at 37 °C than at 4 °C, implying an entrance into the cells by energy-independent and -dependent processes through clathrin-mediated endocytosis. Theoretical predictions support the binding of GK-1 to the hydrophobic pocket of MD2, preventing it from bridging TLR4, thereby promoting receptor dimerization and cell activation. GK-1 can effectively activate cells via a TLR4-dependent pathway based on

Identifiers

PMID39713707
PMCPMC11656211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.